Updated:
Verastem
Brian Stuglik leads Verastem, a Needham oncology biotech that went public in 21 months and bets its entire pipeline on FAK inhibition for solid tumors.
Verastem
Verastem was founded in 2010 by a group of biotech executives led by Christoph Westphal, who previously co-founded Sirtris Pharmaceuticals and sold it to GlaxoSmithKline for $720 million. The firm raised $32 million in a Series A led by Longwood Founders Fund before accelerating to an IPO on Nasdaq in January 2012 — a 21-month sprint from incorporation to public listing that reflected venture-style urgency rather than the measured cadence of established pharmaceutical companies. The company structures itself as a single-asset public vehicle, not a diversified portfolio, meaning its survival depends on success within one narrow biological pathway. The firm directs all deployment toward small-molecule drugs that target cancer stem cells and the tumor microenvironment, specifically through focal adhesion kinase (FAK) and phosphoinositide 3-kinase (PI3K) inhibition. Its lead program, defactinib, an oral FAK inhibitor, has advanced through multiple clinical trials for ovarian cancer, non-small cell lung cancer, and pancreatic cancer — often in combination with other agents. Verastem co-developed duvelisib, an oral PI3K inhibitor, which received FDA approval in 2018 for chronic lymphocytic leukemia and follicular lymphoma, though the company subsequently sold its COPIKTRA (duvelisib) rights to Secura Bio in 2020 for a base payment of $70 million plus milestones. Geographic focus remains concentrated on U.S. clinical trial sites and regulatory pathways, with partnership-driven reach into European and Asian markets through co-development agreements. The company operates from Needham, Massachusetts with a lean organizational footprint appropriate for a clinical-stage biotech rather than a commercial pharmaceutical enterprise. In September 2023, Verastem announced a registered direct offering priced at-the-market under Nasdaq rules, raising approximately $55 million to extend its cash runway through key data readouts for the defactinib program. The firm has collaborated with Amgen on a KRAS G12C inhibitor combination and previously maintained a joint venture with Yakult Honsha for duvelisib development in Japan. Verastem does not operate a venture arm, co-investment platform, or philanthropic foundation — its entire structure is the public-company vehicle itself. What genuinely separates Verastem from other small-cap oncology biotechs is its stubborn commitment to a thesis the rest of the industry discarded: that cancer stem cells and the FAK pathway represent a viable standalone commercial target. Most oncology companies abandoned cancer stem cell biology a decade ago for immuno-oncology and antibody-drug conjugates, but Verastem kept the lab lights on. The financial architecture mirrors this focus — it runs as a single-molecule bet wrapped in the disclosure and liquidity requirements of a Nasdaq listing, which means routine quarterly filings expose exactly how long the runway is and how far the drug has to travel before anyone gets paid.
General information
Firm type
Asset Manager
Year founded
2010
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Needham
Corporate office
Needham, MA, United States
Principals
Brian Stuglik
Chief Executive Officer
Sector focus
Frequently asked questions
What is Verastem's core therapeutic focus?
Verastem concentrates on small-molecule drugs that inhibit focal adhesion kinase (FAK) and phosphoinositide 3-kinase (PI3K) pathways, specifically targeting cancer stem cells and the solid tumor microenvironment. Its lead asset defactinib is being studied in ovarian cancer, non-small cell lung cancer, and pancreatic cancer, often in combination with other targeted therapies. The company does not operate in immuno-oncology, hematology broadly, or infectious disease.
Why did Verastem sell COPIKTRA and what did that transaction look like?
Verastem sold COPIKTRA (duvelisib) to Secura Bio in 2020 for a base consideration of $70 million with additional milestone payments and royalties attached. The divestiture shifted Verastem from a commercial-stage company back to a clinical-stage pipeline, allowing management to concentrate capital on the defactinib program rather than continuing to fund a sales force for a product with a competitive market. The sale also removed commercial revenue, making the company wholly dependent on financing rounds and partnership income.
How does Verastem fund its operations?
Verastem does not generate product revenue following the 2020 sale of its COPIKTRA rights — it funds clinical trials and operations entirely through public equity offerings and partnership agreements. In September 2023, the company raised roughly $55 million through a registered direct offering. Earlier collaboration agreements, such as the duvelisib joint venture with Yakult Honsha and development partnerships with Amgen, have provided non-dilutive milestone cash.
What stage of clinical development is Verastem's lead program in?
Defactinib has advanced through multiple Phase II trials and is currently being evaluated in a late-stage registration-directed study for low-grade serous ovarian cancer in combination with RAF/MEK inhibition. The company has explored defactinib across non-small cell lung cancer, pancreatic cancer, and mesothelioma. As a single-agent, defactinib has shown limited monotherapy activity, which is why the registration path relies on combination regimens.
Does Verastem hold any equity in portfolio companies or operate a venture arm?
Verastem does not operate a venture capital arm or hold equity in external portfolio companies. The firm is structured purely as a Nasdaq-listed drug developer — its balance sheet carries no investment portfolio, no fund commitments, and no external LP capital. Every dollar on the balance sheet is directed toward its own pipeline programs.
What is the relationship between Verastem and Amgen?
Verastem entered a clinical collaboration with Amgen to evaluate defactinib in combination with Amgen's KRAS G12C inhibitor sotorasib (Lumakras) for non-small cell lung cancer. Under the arrangement, Amgen sponsors the trial and provides sotorasib, while Verastem supplies defactinib and shares development costs. The collaboration is non-exclusive and does not grant Amgen any equity or board representation in Verastem.
How is Verastem governed, and who holds decision-making authority?
Brian Stuglik serves as CEO and sits on a board of directors that includes representatives from the firm's early venture backers — Longwood Fund, Bessemer Venture Partners, and Advanced Technology Ventures retained board seats following the 2012 IPO. Clinical and R&D decisions are made by an internal team led by the chief medical officer, with data monitoring committees overseeing trial safety. As a public company, material decisions including financing, partnership, and pipeline prioritization are approved by the board and disclosed in quarterly SEC filings.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: